subscribeSubscribe
Merz wins $185m bid for bankrupt Acorda assets and increases US workforce by 50%

Merz wins $185m bid for bankrupt Acorda assets and increases US workforce by 50%
PHARMACEUTICAL-TECHNOLOGY
11 Jul 2024
Share Share
Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics

Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics
BUSINESSWIRE
10 Jul 2024
Share Share
Acorda files for bankruptcy, inks $185M asset deal to Merz

Acorda files for bankruptcy, inks $185M asset deal to Merz
Zoey Becker FIERCE PHARMA
03 Apr 2024
Share Share
Acorda and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement

Acorda and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
BUSINESSWIRE
01 Apr 2024
Share Share
Biogen returns ex-U.S. rights of MS drug Fampyra to Acorda

Biogen returns ex-U.S. rights of MS drug Fampyra to Acorda
Kevin Dunleavy FIERCE PHARMA
12 Jan 2024
Share Share
NICE opts to reject Acorda’s MS drug Fampyra

NICE opts to reject Acorda’s MS drug Fampyra
John Pinching PHARMATIMES
22 Jun 2022
Share Share
Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
BUSINESSWIRE
09 Mar 2022
Share Share
Acorda Reports Q3 2021 Financial Results, Additions to Leadership Team

Acorda Reports Q3 2021 Financial Results, Additions to Leadership Team
BUSINESSWIRE
09 Nov 2021
Share Share
Acorda offloads manufacturing operations to Catalent for $70M

Acorda offloads manufacturing operations to Catalent for $70M
C. Mitchell ENDPTS
14 Jan 2021
Share Share
Accord Healthcare`s Fampridine Accord (Fampridine) Receives Approval In Europe

Accord Healthcare`s Fampridine Accord (Fampridine) Receives Approval In Europe
EMA
02 Oct 2020
Share Share